RUNX1 and acute myeloid leukemia: Molecular markers, such as fms-like tyrosine kinase 3 (FLT3), nucleophosmin 1 (NPM1), CCAAT/enhancer-binding protein alpha (CEBPA), runt-related transcription factor 1 (RUNX1), additional sex combs like 1, and tumor protein p53 (TP53) genes, were introduced in the latest European LeukemiaNet (ELN) recommendations.[4] Co-occurrence of cytogenetic and molecular abnormalities are frequently present in AML patients.